AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15191618 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Disability Scale Score
Number of subjects: 31
Study 11300387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined femoral and sciatic nerve block with bupivacaine 1 mg x kg(‐1) 7.5 mg x ml(‐1)
Number of subjects: 75
Study 11300387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined femoral and sciatic nerve block with ropivacaine 1 mg x kg(‐1) 7.5 mg x ml(‐1)
Number of subjects: 75
Study 11300387 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia only
Number of subjects: 75
Study 9597417 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 8 micrograms.kg-1
Number of subjects: 23
Study 9597417 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 24 micrograms.kg-1
Number of subjects: 23
Study 9597417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7932943 — intervention group
Group type: EXPERIMENTAL
Intervention: Five‐Step Approach strategy
Number of subjects: 64
Study 7932943 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐awareness strategy
Number of subjects: 64
Study 7932943 — intervention group
Group type: COMPARATOR
Intervention: awareness strategy
Number of subjects: 64
Study 7932943 — intervention group
Group type: COMPARATOR
Intervention: control condition
Number of subjects: 64
Study 3212423 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 17187
Study 3212423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17187
Study 3212423 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and aspirin
Number of subjects: 17187
Study 30496300 — intervention group
Group type: EXPERIMENTAL
Intervention: Connectedness to Nature Index for Parents of Preschool Children (CNI-PPC)
Number of subjects: 299
Study 28062552 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose IIV4 (0.5 mL, 15 µg per strain)
Number of subjects: 2424
Study 26582386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-Generated Index (MGI)
Number of subjects: 678
Study 26582386 — intervention group
Group type: COMPARATOR
Intervention: Comparison instruments (EQ-5D-3 L; Edinburgh Postnatal Depression Scale; Satisfaction With Life Scale; State Trait Anxiety Inventory)
Number of subjects: 678
Study 23325124 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based intervention programme (educational materials and phone counselling)
Number of subjects: 0
Study 23325124 — intervention group
Group type: COMPARATOR
Intervention: Routine care (comparison group)
Number of subjects: 0
Study 23325124 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based intervention programme
Number of subjects: 0
Study 21255503 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 16301
Study 18308010 — intervention group
Group type: EXPERIMENTAL
Intervention: LRPT 150 mg/day
Number of subjects: 444
Study 18308010 — intervention group
Group type: COMPARATOR
Intervention: ERN 1 g
Number of subjects: 444
Study 18308010 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN 1 g coadministered with LRPT 18.75, 37.5, 75, or 150 mg
Number of subjects: 444
Study 18308010 — intervention group
Group type: EXPERIMENTAL
Intervention: LRPT plus ERN
Number of subjects: 444
Study 17101299 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic gastric analysis
Number of subjects: 12
Study 17101299 — intervention group
Group type: COMPARATOR
Intervention: Conventional gastric analysis
Number of subjects: 12
Study 15677415 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of a signal of trust
Number of subjects: 0
Study 15677415 — intervention group
Group type: EXPERIMENTAL
Intervention: Trustworthy behavior (sharing a greater proportion of monetary gains)
Number of subjects: 0
Study 15677415 — intervention group
Group type: COMPARATOR
Intervention: Random monetary transfer
Number of subjects: 0
Study 11691520 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors or angiotensin receptor antagonists
Number of subjects: 369
Study 11691520 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibitors or angiotensin receptor antagonists
Number of subjects: 369
Study 9145959 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid peels (20-70%) and cream containing 10% glycolic acid and 2% hydroquinone (Neostrata AHA Age Spot and Skin Lightening Gel)
Number of subjects: 10
Study 7910999 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil-containing diet
Number of subjects: 30
Study 7910999 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1.62 g EPA and 1.08 g DHA daily)
Number of subjects: 30
Study 7910999 — intervention group
Group type: COMPARATOR
Intervention: Control group (Western diet)
Number of subjects: 30
Study 2906018 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 20
Study 2906018 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 20
Study 30545242 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections
Number of subjects: 192
Study 30545242 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) injections
Number of subjects: 192
Study 29037645 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural insoles
Number of subjects: 24
Study 29037645 — intervention group
Group type: COMPARATOR
Intervention: Placebo insoles (Control)
Number of subjects: 24
Study 26299899 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy and nanocrystalline silver dressings
Number of subjects: 17
Study 26299899 — intervention group
Group type: COMPARATOR
Intervention: Negative pressure wound therapy (NPWT) alone
Number of subjects: 17
Study 23728612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (25 mg)
Number of subjects: 5
Study 23728612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 5
Study 23728612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 21417561 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - 60 min supervised aerobic dance and strength training at least twice per week for a minimum of 12 weeks.
Number of subjects: 105
Study 21417561 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - No specific intervention mentioned.
Number of subjects: 105
Study 19139427 — intervention group
Group type: EXPERIMENTAL
Intervention: tremelimumab 10 mg/kg once every month
Number of subjects: 28
Study 19139427 — intervention group
Group type: EXPERIMENTAL
Intervention: tremelimumab 15 mg/kg every 3 months
Number of subjects: 28
Study 17198089 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradioimmunotherapy with low-dose Interferon-alpha injection before therapy (arm A)
Number of subjects: 44
Study 17198089 — intervention group
Group type: COMPARATOR
Intervention: Control group (arm B)
Number of subjects: 44
Study 15490187 — intervention group
Group type: EXPERIMENTAL
Intervention: FF-CATS
Number of subjects: 40
Study 15490187 — intervention group
Group type: COMPARATOR
Intervention: FACT charts
Number of subjects: 40
Study 12140732 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil, 8-16 mg
Number of subjects: 5000
Study 12140732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study 10025070 — intervention group
Group type: EXPERIMENTAL
Intervention: DFT+ energies
Number of subjects: 83
Study 10025070 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x DFT+
Number of subjects: 83
Study 10025070 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum energy (34 J)
Number of subjects: 83
Study 8050380 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 75 mg tablet (increased to 150 mg if necessary) for 8 weeks
Number of subjects: 181
Study 8050380 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet for 8 weeks
Number of subjects: 181
Study 3291940 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1.0%
Number of subjects: 0
Study 3291940 — intervention group
Group type: COMPARATOR
Intervention: Dipivalyl epinephrine (Propine) 0.1%
Number of subjects: 0
Study 30310037 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Bronchoscopic Navigation (VBN)
Number of subjects: 0
Study 30310037 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation (EMN)
Number of subjects: 0
Study 28295312 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group (treated with stimulant medication)
Number of subjects: 579
Study 28295312 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group with Consistent or Inconsistent medication pattern
Number of subjects: 579
Study 28295312 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group with Consistent pattern
Number of subjects: 579
Study 26394813 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm sealing (EVAS) with the Nellix device
Number of subjects: 25
Study 22540523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education program based on the BASNEF educational model
Number of subjects: 97
Study 22540523 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 97
Study 21180681 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional abutment (PA)
Number of subjects: 25
Study 21180681 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive abutment (DA)
Number of subjects: 25
Study 18788966 — intervention group
Group type: EXPERIMENTAL
Intervention: Legacy intervention (three home visits to construct a personal Legacy, usually a scrapbook with photographs or audiotaped stories)
Number of subjects: 42
Study 18788966 — intervention group
Group type: EXPERIMENTAL
Intervention: Legacy intervention
Number of subjects: 42
Study 18788966 — intervention group
Group type: COMPARATOR
Intervention: Supportive telephone calls (control group)
Number of subjects: 42
Study 17272946 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based program of eating disorder prevention (75 participants)
Number of subjects: 139
Study 17272946 — intervention group
Group type: COMPARATOR
Intervention: Control group (64 participants)
Number of subjects: 139
Study 12811711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine (2.5-10.0 mg)
Number of subjects: 718
Study 12811711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study 12811711 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (7.5 mg)
Number of subjects: 718
Study 12811711 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (2.0 mg)
Number of subjects: 718
Study 11010930 — intervention group
Group type: EXPERIMENTAL
Intervention: Laurate (10 mg/kg body wt)
Number of subjects: 0
Study 11010930 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitate (10 mg/kg body wt)
Number of subjects: 0
Study 11010930 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearate (10 mg/kg body wt)
Number of subjects: 0
Study 11010930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleate (10 mg/kg body wt)
Number of subjects: 0
Study 11010930 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaidate (10 mg/kg body wt)
Number of subjects: 0
Study 11010930 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleate (10 mg/kg body wt)
Number of subjects: 0
Study 11010930 — intervention group
Group type: EXPERIMENTAL
Intervention: Linolenate (10 mg/kg body wt)
Number of subjects: 0
Study 11010930 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl-labeled fatty acids
Number of subjects: 0
Study 11010930 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyl-labeled fatty acids
Number of subjects: 0
Study 8772622 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg b.i.d.
Number of subjects: 34
Study 8772622 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR 100 mg once daily
Number of subjects: 34
Study 8772622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8772622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 34
Study 8772622 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 34
Study 1292771 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and MR cholangiography (MRC) using hepatobiliary contrast media (Mn‐DPDP, Gd‐BOPTA)
Number of subjects: 65
Study 1292771 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound, CT, and invasive techniques (ERCP)
Number of subjects: 65
Study 6721260 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysed alum adsorbed extract of grass pollens
Number of subjects: 58
Study 6721260 — intervention group
Group type: COMPARATOR
Intervention: Allpyral (undialysed pyridine extracted alum precipitated extract of grass pollens)
Number of subjects: 58
Study 6721260 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 58
Study 30262574 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tinzaparin 100 IU·kg‐1 once a day for 12 weeks
Number of subjects: 549
Study 30262574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment in addition to standard of care)
Number of subjects: 549
Study 24453078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (100 mg, 300 mg, or 700 mg)
Number of subjects: 38
Study 24453078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 22417028 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative beta-blockade
Number of subjects: 8351
Study 22417028 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative beta-blockers
Number of subjects: 8351
Study 22417028 — intervention group
Group type: COMPARATOR
Intervention: No perioperative beta-blockers (Control)
Number of subjects: 8351
Study 20431994 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative conditioning procedure pairing alcohol-related cues with negative stimuli
Number of subjects: 0
Study 20431994 — intervention group
Group type: COMPARATOR
Intervention: Evaluative conditioning procedure pairing alcohol-related cues with neutral stimuli
Number of subjects: 0
Study 18560788 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) 2 x 15 g/day for 2 weeks
Number of subjects: 20
Study 18560788 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch with Wheat Bran (RS+WB) 2 x 15 g RS + 2 x 6 g WB
Number of subjects: 20
Study 18560788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15834291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (calcium antagonist)
Number of subjects: 2259
Study 15834291 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 2259
Study 15834291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional quality control
Number of subjects: 2259
Study 15834291 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal quality control
Number of subjects: 2259
Study 12804926 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose AR‐H040922 (13.3 microg/kg/min)
Number of subjects: 82
Study 12804926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose AR‐H040922 (6.7 microg/kg/min)
Number of subjects: 82
Study 12804926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 12804926 — intervention group
Group type: EXPERIMENTAL
Intervention: AR‐H040922 (both doses)
Number of subjects: 82
Study 10821460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin replacement therapy
Number of subjects: 40
Study 10821460 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunoglobulin replacement therapy
Number of subjects: 40
Study 8899085 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg loperamide
Number of subjects: 16
Study 8899085 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg loperamide
Number of subjects: 16
Study 8899085 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sugar measurement
Number of subjects: 16
Study 1739446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen infusion
Number of subjects: 6
Study 1739446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6861809 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 0
Study 6861809 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin retard
Number of subjects: 0
Study 30111222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application assistance (AED-Quebec)
Number of subjects: 52
Study 30111222 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal assistance
Number of subjects: 52
Study 30111222 — intervention group
Group type: COMPARATOR
Intervention: No assistance
Number of subjects: 52
Study 30377212 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity programme supported by behavioural change techniques (8 visits of supervised activity sessions and 12 telephone support calls over 12 weeks)
Number of subjects: 0
Study 30377212 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 26930534 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Balance treatment intervention (n = 60)
Number of subjects: 122
Study 26930534 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (n = 62)
Number of subjects: 122
Study 26930534 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study 25108493 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary anatomy assessment via blinded film review
Number of subjects: 1787
Study 25108493 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization strategy assessment via blinded film review
Number of subjects: 1787
Study 25108493 — intervention group
Group type: COMPARATOR
Intervention: SYNTAX score comparison across revascularization strategies
Number of subjects: 1787
Study 22955097 — intervention group
Group type: EXPERIMENTAL
Intervention: Twenty‐ to 30‐minute brief intervention (education and motivational interview)
Number of subjects: 104
Study 20676609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereboost™ (100 mg)
Number of subjects: 32
Study 20676609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereboost™ (200 mg)
Number of subjects: 32
Study 20676609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereboost™ (400 mg)
Number of subjects: 32
Study 20676609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereboost™ (100 mg, 200 mg, 400 mg)
Number of subjects: 32
Study 20676609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17430413 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 19
Study 17430413 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 19
Study 16317275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 10
Study 16317275 — intervention group
Group type: COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy (3DCRT)
Number of subjects: 10
Study 12206264 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency tissue ablation (2,800 J per treatment session under local anesthesia)
Number of subjects: 20
Study 12206264 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency tissue ablation
Number of subjects: 20
Study 10986574 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group (patients and their partners, n = 16)
Number of subjects: 29
Study 10986574 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients only, n = 13)
Number of subjects: 29
Study 8615349 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training (2 days/week, 5 different exercises)
Number of subjects: 39
Study 8615349 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 39
Study 1447035 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (chemotherapy (5‐FU/FAM) alone, radiation therapy alone, or chemotherapy+radiation therapy)
Number of subjects: 120
Study 1447035 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 120
Study 1447035 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 120
Study 1447035 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (chemotherapy and radiation therapy)
Number of subjects: 120
Study 1447035 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (radiation)
Number of subjects: 120
Study 1447035 — intervention group
Group type: COMPARATOR
Intervention: No radiation
Number of subjects: 120
Study 3905064 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 768
Study 3905064 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 768
Study 31537107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant (100 mg, 2 x 50 mg tablets)
Number of subjects: 518
Study 31537107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 31537107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Number of subjects: 518
Study 29895072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully Covered Self-Expandable Metal Stent (FC-SEMS)
Number of subjects: 98
Study 29895072 — intervention group
Group type: COMPARATOR
Intervention: Partially Covered Self-Expandable Metal Stent (PC-SEMS)
Number of subjects: 98
Study 26311660 — intervention group
Group type: EXPERIMENTAL
Intervention: Staggered meal (86g beans consumed 15min before the rest of the meal)
Number of subjects: 28
Study 26311660 — intervention group
Group type: COMPARATOR
Intervention: Control meal (86g beans consumed with the rest of the meal)
Number of subjects: 28
Study 25514077 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomized buccal midazolam (0.3 mg/kg)
Number of subjects: 25
Study 25514077 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomized intranasal midazolam (0.3 mg/kg)
Number of subjects: 25
Study 22776782 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Hemodialysis (eHD)
Number of subjects: 8
Study 22776782 — intervention group
Group type: COMPARATOR
Intervention: Conventional Hemodialysis (cHD)
Number of subjects: 8
Study 19857542 — intervention group
Group type: EXPERIMENTAL
Intervention: Funciona™ (antioxidant functional food beverage)
Number of subjects: 400
Study 19857542 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise
Number of subjects: 400
Study 17608947 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic stenting as bridge to elective surgery
Number of subjects: 120